FDA clears AI-powered vascular imaging software
Nov 05, 2025 by Bailey G. Salimes, CRTonline.org
The U.S. Food and Drug Administration (FDA) approved initiation of the PARADIGM trial this week, which is evaluating the Anteris DurAVR® transcatheter heart valve (THV) for patients with severe calcific aortic stenosis (AS).
Nov 05, 2025 by Nathan Gray, CRTonline.org
Comprehensive lifestyle and risk factor modification reduced atrial fibrillation recurrence by 47% in the 12 months following catheter ablation compared to usual care, with 61.3% of patients in the intervention group remaining arrhythmia-free versus 40% receiving standard management, reports the first randomized trial of aggressive risk factor reduction in the ablation setting.
Nov 05, 2025 by Will Chu, CRTonline.org
A new meta-analysis questions the long-held belief that an invasive strategy for patients with non–ST-segment elevation myocardial infarction (NSTEMI) always provides superior outcomes.